About the study

To demonstrate that CT-P13 is equivalent to China-approved Remicade at Week 14, in terms of efficacy as determined by clinical response according to the change from baseline in disease activity.

Who can take part?

You may be eligible to participate in the study if you meet the following criteria:

Inclusion criteria

1. Has a diagnosis of rheumatoid arthritis
2. Has active disease as defined in DAS28 Criteria

Exclusion criteria

1. Has a history of tuberculosis (TB) or a current diagnosis of TB
2. Has previously received a biological agent
3. Has previously received a tumor necrosis factor alpha (TNF α) inhibitor
4. Allergies to any of the excipients of infliximab or hypersensitivity to murine and/or human proteins or immunoglobulin products
5. Pregnant or lactating

For a full list of inclusion/exclusion criteria, please visit ClinicalTrials.gov

Study locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to apply

Determine if a study site for this clinical trial is near you. Contact the study to apply.